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Abstract
Background: Herpes simplex virus (HSV) is a common human pathogen that causes a variety of diseases, including
oral-labial, genital lesions and life-threatening encephalitis. The antiviral nucleoside analogues such as acyclovir are
currently used in anti-HSV therapies; however, clinical overuse of these drugs has led to the emergence of
drug-resistant viral strains. Hence, there is an urgent need to develop new anti-HSV agents.
Methods: To identify novel anti-HSV-1 compounds, we screened the LOPAC small scale library of 1280 bioactive
compounds to identify inhibitors of HSV-1-induced necroptosis. Further experiments including western blot analysis,
Q-PCR analysis and immunohistochemistry were performed to explore the antiviral mechanism of the compounds.
Results: Here, we identified PHA767491 as a new inhibitor of HSV. PHA767491 potently blocked the proliferation of
HSV in cells, as well as HSV induced cell death. Further, we found that PHA767491 strongly inhibited HSV infection
post viral entry. Moreover, PHA767491 reduced the expression of viral genes required for DNA synthesis including
UL30/42 DNA polymerase and UL5/8/52 helicase-primase complex. The essential immediate early (IE) genes such as
ICP4 and ICP27 are critical for the expression of the early and late genes. Of note, PHA767491 inhibited the
expression of all IE genes of both HSV-1 and HSV-2. Importantly, PHA767491 reduced viral titers in the tissues from
the mice infected with HSV-1. Consistently, immunohistochemistry analysis showed that PHA767491 dramatically
attenuated expression of viral protein gB in the livers.
Conclusions: Taken together, PHA767491 has potent anti-HSV activity by inhibiting viral replication both in vitro
and in mouse model. Thus, PHA767491 could be a promising agent for the development of new anti-HSV therapy.
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Background
Herpes simplex virus (HSV) is a group of common
human pathogen that causes a variety of clinical mani-
festations including oral-labial and genital lesions, karati-
tis and life-threatening encephalitis [1–3]. After primary
infection, HSV usually establishes a latent infection in
sensory neurons throughout the entire life of the host.
This latent infection can be reactivated, resulting in
recurrent diseases. HSV is divided into two serotypes,
HSV type 1(HSV-1) and type 2(HSV-2), that are the
major causes of oral-labial and genital herpes, respect-
ively. In the world, above 80% adults and 20% adults are
infected with HSV-1 and HSV-2, respectively. Immuno-
compromised patients lean to HSV infection and suffer
recurrence [4–7].
HSV is enveloped double-strand DNA virus possessing
a large genome of around 150k nucleotides. The HSV
genome encodes approximately 80 proteins. HSV-1 and
HSV-2 share around 80% sequence identity in the
protein-coding region. After the HSV virus enters the
cytoplasm of the infected cell, the viral genome is
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released into cell nucleus [8, 9]. Then the linear viral
genome transforms to a circular genome and initiates
DNA replication at origins of DNA replication [10]. The
viral replication is a precisely organized event. Some
HSV viral proteins are known to be necessary for viral
DNA synthesis, including proteins encoded by UL5,
UL8, UL29, UL30, UL42 and UL52 genes [11–14]. UL9
assists to unwind the DNA strains by binding to the
origins of DNA replication. ICP8, encoded by the UL29
gene, is the major HSV single-strand DNA-binding pro-
tein of HSV. UL30 and UL42 are two subunits of DNA
polymerase. UL5, UL8 and UL52 constitute helicase-
primase complex. HSV genes are expressed in sequential
phases termed immediate early (IE), early and late.
There are five IE genes: ICP0, ICP4, ICP22, ICP27 and
ICP47. Numerous studies have shown that HSV IE genes
play important roles in regulating the expression of viral
early genes. Most of the early genes are involved in the
viral DNA replication. For example, deletion of ICP4 or
ICP27 significantly impairs the expression of early and
late viral genes [15–17]. Therefore, inhibition of these
essential IE genes leads to defective viral replication.
A lot of efforts have been focused on the development
of anti-HSV therapeutic agents. The antiviral nucleoside
analogue acyclovir is the most common drug used for
the treatment of HSV infection. Acyclovir can be phos-
phorylated by viral thymidine kinase and cellular kinases.
The product acyclovir triphosphate selectively inhibits
viral DNA polymerase to hinder elongation of viral
DNA [18]. Penciclovir and foscarnet have a similar
mechanism of action to acyclovir and thus are generally
used for the treatment of herpesvirus infections [19, 20].
However, there is increasing evidence that these therap-
ies have led to the emergence of drug-resistant mutant
strains of HSV [21]. Therefore, it is an urgent need to
develop new effective anti-HSV agents.
PHA767491 is reported as an anti-tumor drug, which in-
duce apoptosis in certain type of cancer cell lines [22–25].
In the current study, we identified PHA767491 as a potent
inhibitor of HSV-1 and HSV-2. PHA767491 effectively
inhibited the proliferation of HSV and viral replication in
multiple cells. PHA767491 showed a strong inhibitory
effect on the expression of the essential HSV IE genes such
as ICP4 and ICP27, therefore leading to suppression of viral
replication. Importantly, PHA767491 significantly attenu-
ated HSV-1 replication in mouse model.
Methods
Study design
To identify novel anti-HSV-1 compounds, we screened
more than 1000 compounds for some antiviral drugs by
using the model in which HSV-1 directly induced necro-
sis of L929. To test the effect of compounds to suppress
HSV, plaque forming assay and west blot assay were
performed. We further explored the antiviral mechanism
of the compounds by using the experiments including
Q-PCR analysis, immunofluorescent staining and immu-
nohistochemistry analysis.
Viruses and reagents
HSV-1 KOS strain was from Dr. Sandra K. Weller.
(University of Conecticut Health Center) and GFP-
labeled HSV-1 F strain was from Dr. Chunfu Zheng
(Soochow University). LOPAC small scale library of
1280 bioactive compounds, LPS and Poly (I:C) were
purchased from Sigma Aldrich. Necrostatin-1 was
purchased from Alexis Biochemicals. Z-VAD were
purchased from WuXi AppTec. The smac mimetic
compound were from Dr. Xiaodong Wang (National
institute of biological sciences).
Antibodies
The following antibodies were used: anti-VP16 monoclo-
nal antibody (ab110226; Abcam), anti-gB monoclonal
antibody (ab6505; Abcam), anti-β-actin monoclonal
antibody (Sigma-Aldrich), anti-P65 polyclonal antibody
(F0514; Santa Cruz), secondary antibody (Sigma-Aldrich),
anti-phospho-IκB-α monoclonal antibody (9246; Cell
Signaling), anti-Phospho-P65 monoclonal antibody (3033p;
Cell Signaling), anti-phospho-JNK monoclonal antibody
(9251; cell signaling), anti-ICP6 polyclonal antibody
was generated in rabbit by immunization with recom-
binant ICP6 N-terminal polypeptide. Secondary anti-
body binding to Alexa Fluor 488 was purchased from
Life Technologies.
Antiviral activity assay
L929 Cells were seeded into 96-well plates at the dens-
ity of 8 × 104. L929 cells were pretreated with com-
pounds (10μM) for 1h and then were infected with
HSV-1(MOI = 2) for addition 18h. Cell viability was
determined by using Cell Titer-Glo Luminescent cell
viability assay kit (Promega) according to the product
instructions. Antiviral activities of compounds were
calculated as a percentage of viability of control.
Western blot analysis
Cell pellet was collected by centrifugation at 13000 × g
for 1 min and resuspended in lysis buffer (20mM
Tris–HCl, PH 7.4, 150mM NaCl, 10% glycerol, 1%
Triton X-100, 1mM Na3VO4, 25mM β-glycerol-
phosphate, 0.1mM PMSF, a complete protease inhibi-
tor set) (Roche). The re-suspended cell pellet was
vortexed for 20s and lysed on ice for 20 min. Cell
lysates were centrifuged at 13000 × g for 20 min at 4°C.
The supernatants were collected and subjected to
western blot analysis. The proteins was detected by
using appropriate antibody.
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Cell infected with GFP-labeled virus imaging
Cell were seeded into the 6-well plates at a density of
3 × 106/well and were infected with GFP-labeled HSV-
1(MOI = 2) for 8h. The images were obtained with a
Leica DMILLED inverted microscope.
Q-PCR analysis
Total RNA was extracted with TRIzol (Invitrogen) and
reverse-transcribed into cDNA according to the procedure
of RevertAid First Strand cDNA kit (Thermo). Gene ex-
pression was detected by qPCR analysis with SYBR Green
PCR Master Mix (Applied Biosystems). The results were
analyzed by Applied Biosystems 7500 Fast Real Time PCR
System. The sequence of the PCR primers used in Q-PCR
analysis were shown in Table 1.
Drug treatment and mice infection
DMSO or PHA767491 were diluted with sterile phosphate-
buffered saline (PBS). Eight-week-old RIP3 KO mice were
pretreated with DMSO or PHA767491 (25mg/Kg) via
i.p. injection for 1h. Then the mice were infected
with HSV-1 with 2 × 107 plaque forming units by i.p.
injection. Mice were sacrificed 48 h after the HSV-1
injection and the Livers and spleens of mice were ex-
cised for virus titer test or immunohistochemistry
analysis.
Determination of viral titers in organs of mice infected
with HSV-1
Livers and spleens of mice infected with HSV-1 were
ground to homogenates. The homogenates were thawed
and frozen three times to fully release the viral particle.
Then the homogenates were spin at 600 × g for 5 min.
The supernatant were collected and analyzed by plaque
forming assay in vero cells.
Immunohistochemistry analysis
Liver sections from DMSO or PHA767491 pretreated
mice were processed by paraffin embedding and
stained with anti-gB antibody. To detect the replica-
tion of HSV-1, the slices were visualized with DAB
(Genetech).
Immunofluorescent staining
Cells were seeded in culture plates. After the TNF-α
treatment, cells were washed with PBS, followed by
fixation in 4% paraformaldehyde for 10 min. Then
the cells were washed three times with PBS followed
by incubation with 0.25% Triton X-100 in PBS for
10 min. The cells were blocked for 30 min with
5%BSA in PBS and stained with primary and second-
ary antibody successively. Nuclei was stained with
DAPI. Images ware captured with a Leica confocal
microscope.
Statistical analysis
Data of antiviral activity are represented as the mean +
SD of duplicates. All experiments were repeated at least
twice with same results. Significance of difference was
evaluated by T tests (Graphpad prism software).
Results
Screening of small-molecule inhibitors against HSV-1
Our previous study has shown that HSV-1 infection nat-
urally triggers programmed necrosis (termed necroptosis)





































Hou et al. BMC Infectious Diseases  (2017) 17:217 Page 3 of 9
in mouse fibroblast L929 cells [26]. This process requires
effective HSV-1 replication. So compounds with anti-
HSV-1 activities can cause reduced necroptosis and in-
creased cell viability of HSV-1-infected L929 cells. To
identify novel anti-HSV-1 compounds, we screened the
LOPAC small scale library of 1280 bioactive compounds
to identify inhibitors of HSV-1-induced necroptosis.
PHA767491 was identified as one of the most effective
hits that significantly inhibited HSV-1 induced necrosis
(Fig. 1a and b). Further, we confirmed that PHA767491
efficiently blocked HSV-1 induced necrosis in a dose-
dependent manner, with an estimated IC:50 value of 1.86
μM (Fig. 1c). Next, to evaluate the effect of PHA767491
on HSV-1 proliferation in cells, L929 cells were treated
with PHA767491 prior to infection with GFP-labeled
HSV-1. As shown in Fig. 1d, PHA767491 potently reduced
the proliferation of GFP-labeled HSV-1 in cells, indicating
an antiviral activity of PHA767491 against HSV-1.
PHA767491 does not block TNF-α induced or TLR-induced
necrosis
It is well known that necroptosis can be induced by the
activation of death receptors or Toll-like receptors (TLR)
[27–31] in addition to HSV-1 infection. We found that
PHA767491 did not inhibit TNFR induced necroptosis in
L929 cells (Fig. 2a) or TLR-induced necroptosis in macro-
phages (Fig. 2b), suggesting that PHA767491 does not
affect common signaling molecules in the necroptosis
pathway. These results suggest that PHA767491 blocks
HSV-1 proliferation.
PHA767491 reduces viral titers and expression of HSV-1
proteins in various cell lines
To further confirm the antiviral activity of PHA767491
against HSV-1, we analyzed viral titer and viral proteins
in HSV-1 infected cells in the presence of PHA767491.
Using plaques forming assay, we clearly clarified that
PHA767491 decreased the viral titer of HSV-1 in mouse
L929 and MEFs (Fig. 3a and b). The similar inhibitory
effect of PHA767491 on HSV-1 viral titer was observed
in human cervical cancer HeLa and gliblastoma T98G
cells (Fig. 3c and d). In addition, western blotting ana-
lysis showed that PHA767491 efficiently blocked the
expression levels of the envelop glycoprotein gB and
viral ribonucleotide reductase large subunit ICP6 in all
of these examined mouse and human cell lines (Fig. 3e
and f). Taken together, these results demonstrate that
PHA767491 efficiently reduces HSV-1 viral proteins and
viral titers.
PHA767491 blocks HSV-1 infection post viral entry
Next, we investigate whether PHA767491 blocks HSV-1
infection at viral entry or post viral entry. L929 cells
were infected with HSV-1 for 1h. After the entry of
HSV-1 into the cells, viruses in the medium were
washed away and then cultured cells in fresh medium
containing DMSO or PHA767491 for additional 8h
(Fig. 4a). Notably, PHA767491 efficiently blocked ex-
pression of viral proteins such as gB and ICP6 in
multiple cell lines after virus entry (Fig. 4b, c and d).
















































Fig. 1 Screening of small-molecule inhibitors against HSV-1 induced necroptosis. a L929 cells were pretreated with compounds (10μM) from a
library of 1280 chemicals for 1 h and subsequently infected with HSV-1 at a multiplicity of infection (MOI) value of 2 for 20h. Cell viability was
assessed by measuring ATP levels. b The chemical structure of PHA767491. c L929 cells were pretreated with the indicated concentrations of
PHA767491 for 1h and then treated with PBS or HSV-1 (MOI = 2) for 20 h and cell viability was measured. d L929 cells were pretreated
with DMSO or PHA767491 for 1h and then infected with GFP-labeled HSV-1 for 16h. The fluorescence intensity was analyzed via inverted
fluorescence microscopy
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induced necrosis even after HSV-1 entry (Fig. 4e). Thus,
PHA767491 inhibited HSV-1 infection post virus entry.
PHA767491 inhibits the expression of immediate-early
viral genes
Studies have shown that HSV-1 replication is regulated
by some viral proteins such as UL30/42 DNA polymer-
ase and UL5/8/52 helicase-primase complex [11–14].
We evaluated the expression of these genes in the pres-
ence of PHA767491. Quantitative PCR analysis showed
that PHA767491 remarkably reduced expression of UL5,
UL8, UL29, UL30, UL42 and UL52 in the HSV-1 in-
fected cells (Fig. 5a). It is known that HSV immediate
early (IE) genes regulate the expression of early and late
viral genes. We further examined the effect of PHA767491
on the essential HSV-1 IE genes expression including ICP0,
ICP4 and ICP27. As shown in Fig. 5b, the expression levels
of ICP0, ICP4, ICP22, ICP27 and ICP47 were greatly inhib-
ited in cells treated with PHA767491. These results suggest
that PHA767491 inhibits HSV-1 replication through the
suppression of immediate early gene expression.
PHA767491 suppresses HSV-2 IE gene expression, viral
replication and HSV-2 induced necrosis
To further address whether PHA767491 could block
HSV-2 replication, cells were pretreated with DMSO or
PHA767491 and infected with HSV-2. Notably, HSV-2















































Fig. 2 PHA767491 does not block TNF-α induced or TLR-induced necrosis. a L929 cells were pretreated with DMSO or PHA767491 (10μM) for 1h
and then treated with TNF-α (10ng/ml) plus z-VAD (20μM) for 14 h and cell viability was measured. b BMDM were pretreated with DMSO or
PHA767491 (10μM) for 1h and then treated with LPS (20ng/ml) or Poly(I:C) (20μg/ml) plus z-VAD(10μM) for 16 h and cell viability was measured.





















































































































Fig. 3 PHA767491 reduces viral titers and expression of HSV-1 proteins in various cell lines. L929 cells and HeLa cells were pretreated with DMSO
or PHA767491 for 1h prior to infection with HSV-1(MOI = 2) for 8h. The viral titers for L929 (a), MEF (b), HeLa (c) and T98G (d) were analyzed via
plaque forming assays. The expression levels of the HSV-1 proteins ICP6 and gB in L929 cells (e) or HeLa cells (f) were measured by western
blot analysis
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PHA767491 at the concentration of 3μM (Fig. 6a).
Moreover, we found PHA767491 caused the inhibition
of HSV-2 IE gene expression (Fig. 6b). Consistently,
PHA767491 significantly blocked HSV-2 induced cell
death (Fig. 6c). Thus, PHA767491 is a novel agent
against both HSV-1 and HSV-2 viral replication.
PHA767491 significantly attenuates HSV-1 replication in
mouse model
We have previously shown that HSV-1 infection triggers
necroptosis in non-natural host mouse cells, but not in
natural host human cells [26, 32, 33]. Thus, RIP3-
deficient mouse is a more relevant model for the study
of HSV-1 infection in vivo. To assess the effect of
PHA767491 on HSV-1 replication in mouse model, we
injected RIP3-deficient mice with vehicle or PHA767491
followed by HSV-1 infection. Compared with vehicle
treatment, PHA767491 reduced viral titer in livers and
spleens from RIP3-deficient mice infected with HSV-1
(Fig. 7a and b). Further immunohistochemistry analysis
confirmed that PHA767491 dramatically attenuated
expression of viral protein gB in the livers (Fig. 7c).
These results indicate that PHA767491 exhibits prom-
ising therapeutic activity against HSV-1 infection in
mouse model.
Discussion
Uncontrolled HSV infection always lead to some severe
diseases such as gingivostomatitis [2, 34, 35] and en-













































































Fig. 4 PHA767491 inhibits HSV-1 induced necroptosis and the expression levels of viral proteins after HSV-1 entry. a Schematic view. L929 cells
(b), T98G cells (c), and HeLa cells (d) were infected with HSV-1(MOI = 4) for 1h. The cells were washed with PBS and then cultured in virus free
medium containing with DMSO or PHA767491 for an addition 8h. The expression levels of the HSV-1 proteins gB and ICP6 were measured by
western blot analysis. e L929 cells were infected with HSV-1 (MOI = 4) for 2h and then washed once with PBS. The cells were then cultured in












































Fig. 5 PHA767491 suppresses the expression of HSV immediate early genes. a, b L929 cells were pretreated with DMSO or PHA767491 for 1h and
then infected with HSV-1 (MOI = 2) for 2h. The expression of indicated genes were measured by quantitative PCR
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PHA767491 as a new anti-HSV agent that potently
blocks viral replication of HSV-1 and HSV-2. Our in
vivo study revealed a strong inhibition of HSV-1 produc-
tion by PHA76749 in the mice infection model. Thus,
PHA767491 could be a promising agent for the develop-
ment of new anti-HSV therapy.
One complete cycle for HSV replication need a series of
steps including viral attachment and penetration, viral repli-
cation, and viral release. Intervention in these processes
provides effective protection against HSV infection. Thea-
flavin digallate has shown to prevent HSV-1 from entering





















































Fig. 6 PHA767491 suppresses HSV-2 IE gene expression, viral replication and HSV-2 induced necrosis. a L929 cells were pretreated with DMSO or
PHA767491 at the indicated concentrations for 1h and infected with HSV-2 (MOI = 2) for 10h, the cell lysates were collected and subjected to
western blot analysis. b L929 cells were pretreated with DMSO or PHA767491 for 1h and then infected with HSV-2 (MOI = 2) for 2h. The expression of
indicated proteins were measured by quantitative PCR. c L929 cells were pretreated with DMSO or PHA767491 for 1h and infected with


















Fig. 7 PHA767491 attenuates HSV-1 viral titers in animal model. RIP3 knockout mice were pretreated with DMSO or PHA767491 via intraperitoneal
injection and infected with HSV-1 of 2× 107 pfus per mouse by intraperitoneal injection for 2 days. The viral titers in livers (a) and spleens (b)
were determined by plaque assay. c The viral titers in the livers from RIP3 knockout mice were measured by immunohistochemistry. Arrows
indicated the expression of viral protein gB. The results shown here are representative of seven mice (n = 7 per group)
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analogues such as acyclovir, penciclovir and foscarnet inter-
fere with the viral DNA synthesis to attenuate HSV infec-
tions [18–20]. In this study, we found PHA767491
remarkably reduced the expressions of HSV-1 proteins
including ICP6 and gB and viral titer in multiple cell lines
even after the entry of HSV into the host cells. Similar in-
hibition of HSV-2 infection by PHA767491 was observed
at the post-viral entry stage. These results demonstrate that
PHA767491 effectively blocks HSV replication.
HSV replication is regulated by viral proteins. At least
several viral proteins are required for viral DNA synthe-
sis, including proteins encoded by UL5, UL8, UL29,
UL30, UL42 and UL52 genes. We found PHA767491
strongly inhibited the expression of these genes. HSV IE
genes are expressed earliest after infection without the
requirement of viral protein synthesis [3]. The essential
IE genes such as ICP4 and ICP27 are critical for the
efficient expression of the early and late genes. Of note,
we found that PHA767491 significantly impaired the
expression of all IE genes. The levels of ICP27 RNA and
protein were very low or undetectable in the presence of
PHA767491. Therefore, PHA767491 disrupts HSV repli-
cation by intervening in IE gene expression or upstream
signaling molecules regulating IE gene expression.
In addition to viral proteins, NF-κB signals and MAPK
signals of host cells are critical for virus replication at
the early stage of infection [40–43]. The natural product
harmine has been shown to inhibit HSV replication by
downregulating both NF-κB and MAPK pathways [44].
However, in our study, PHA767491 did not affect the
NF-κB activation (Additional file 1: Figure S1 A and B).
Furthermore, we found that PHA767491 had no effects
on the activations of ERK, p38 and JNK, three critical
kinases of MAPK (Additional file 1: Figure S1 C, D
and E). Thus, PHA767491 exhibits anti-HSV activity
without affecting cellular NF-κB and MAPK pathways.
Conclusion
In this study, we identified PHA767491 as a new inhibi-
tor of HSV. PHA767491 potently blocked the proli-
feration of HSV in various human and mouse cells,
including HSV-1 and HSV-2. Moreover, PHA767491 sig-
nificantly reduced the expression of viral genes required
for DNA synthesis including UL30/42 DNA polymerase
and UL5/8/52 helicase-primase complex. Moreover,
PHA767491 also inhibited the expression of all IE genes
of both HSV-1 and HSV-2. Importantly, PHA767491 re-
duced viral titers in the tissues from RIP3-deficient mice
infected with HSV-1. Consistently, immunohistochemis-
try analysis showed that PHA767491 dramatically atten-
uated expression of viral protein gB in the livers. Further
studies will be required to understand the precise
molecular mechanism through which PHA767491 con-
trols the expression of IE genes.
Additional file
Additional file 1: Figure S1. PHA767491 has no effect on NF-κB and
MAPK activation. (DOCX 526 kb)
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